Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2760-2776

  Ma, Brigette B Y ^a   Bristow, Robert G ^a   Kim, John ^a   Siu, Lillian L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT;

ANGIOGENESIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CLINICAL RESEARCH; CLINICAL TRIAL; DNA REPAIR; HUMAN; INFLAMMATION; IONIZING RADIATION; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; ADJUVANT THERAPY; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; GENE THERAPY; GENE VECTOR; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; RADIATION DOSE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042631357     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.044     Document Type: Review

References (209)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
2. Rosen EM, Fan S, Goldberg ID, et al: Biological basis of radiation sensitivity: Part 2. Cellular and molecular determinants of radiosensitivity. Oncology (Huntingt) 14:741-757, 2000
3. Coleman CD: Clinical applications of molecular biology in radiation oncology. Semin Radiat Oncol 6:245-249, 1996
4. Marples B, Greco O, Joiner MC, et al: Molecular approaches to chemo-radiotherapy. Eur J Cancer 38:231-239, 2002
5. Brown JM: Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 49:319-326, 2001
6. Schmidt-Ullrich RK, Contessa JN, Dent P, et al: Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 7:321-330, 1999
7. Steel GG, Peckham MJ: Exploitable mechanism in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979
8. West CM, Davidson SE, Roberts SA, et al: The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 76:1184-1190, 1997
9. Deacon J, Peckham MJ, Steel GG: The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 2:317-323, 1984
10. Milas L, Kishi K, Hunter N, et al: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501-1504, 1999
11. Petersen C, Petersen S, Milas L, et al: Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 6:2513-2520, 2000
12. Kwok TT, Sutherland RM: Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 64:251-254, 1991
13. Soldatenkov VA, Dritschilo A, Wang FH, et al: Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J Sci Am 3:13-20, 1997
14. Grandhi R, Chakraborty A, Melhem MF, et al: Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous cell carcinoma but not normal mucosal epithelial cells. Oncogene 15:409-416, 1997
15. Bristow RG, Hill RP: Molecular and cellular basis of radiotherapy, in Tia HR (ed): The Basic Science of Oncology. New York, NY, McGraw-Hill, 1998, pp 295-322
16. Coleman CN: Radiation oncology: Linking technology and biology in • the treatment of cancer. Acta Oncol 41:6-13, 2002
17. Schmitt CA, Friedman JS, Yang M, et al: Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298, 2002
18. Khanna KK, Lavin MF, Jackson SP, et al: ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 8:1052-1065, 2001
19. van Gent DC, Hoeijmakers JH, Kanaar R: Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2:196-206, 2001
20. Fernandez-Capetillo O, Chen HT, Celeste A, et al: DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 4:993-997, 2002
21. Sartor C: Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Semin Oncol 27:15-20, 2000
22. Slichenmyer WJ, Fry DW: Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 28:67-79, 2001
23. Haffty BG, Brown F, Carter D, et al: Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case control study. Int J Radiat Oncol Biol Phys 35:751-757, 1996
24. Harari PM, Huang SM: Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289, 2001
25. Dent P, Reardon DB, Park JS, et al: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell deaths. Mol Biol Cell 10:2493-2506, 1999
26. Wollman R, Yahalom J, Maxy R, et al: Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 30:91-98, 1994
27. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 1999
28. Raben D, Phistry M, Helfrich B: ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), enhances radiation induced cytotoxicity in human pancreatic and cholangio-carcinoma cell lines in vitro. Gastrointestinal Cancer Research Conference, Orlando, FL, November 16-18, 2000 (abstr)
29. Raben D, Helfrich B, Chan D, et al: The effects of ZD1839 on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitro. Proceedings of the 2CXD1 AACR-NCI-EORTC International Conference. October 29-November 2, 2001, Miami Beach, FL (abstr 756)
30. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174, 2000
31. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999
32. Raben D, Helfrich B, Chan D, et al: C225 anti-EGFR antibody potentiates radiation and chemotherapy cytotoxicity in human non-small cell lung cancer cells in vitro and in vivo. Proc Am Soc Clin Oncol 20:257a, 2001 (abstr 1026)
33. Bonner JA, Raisch KP, Trummell HQ, et al: Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18:47S-53S, 2000 (suppl)
34. Bianco C, Bianco R, Tortora G, et al: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6:4343-4350, 2000
35. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
36. Saleh MN, Raisch KP, Stackhouse MA, et al: Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14:451-463, 1999
37. Nasu S, Ang KK, Fan Z, et al: C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51:474-477, 2001
38. Raben D, Buchsbaum DJ, Gillespie Y: Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. Proc Am Assoc Cancer Res 40:184, 1999 (abstr 1224)
39. Williams KJ, Tefler BA, Stratford J, et al: ZD1839 ("tressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86:1157-1161, 2002
40. Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519-1528, 2000
41. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001
42. Baselga J: The EGFR as a target for anticancer therapy: Focus on cetuximab. Eur J Cancer 37:S16-S22, 2001 (suppl)
43. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al: The Ras radiation resistance pathway. Cancer Res 61:4278-4282, 2001
44. Jones HA, Hahn SM, Bernhard E, et al: Ras inhibitors and radiation therapy. Semin Radiat Oncol 11:328-337, 2001
45. Rowinsky EK, Jolene JW, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anti-cancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
46. Hahn SM, Bernard E, McKenna WG: Farnesyltransferase inhibitors. Semin Oncol 28:86-93, 2001
47. Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: A conserved switch for diverse cell functions. Nature 348:125-132, 1990
48. McKenna WG, Weiss MC, Bakanauskas VJ, et al: The role of H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849-859, 1990
49. Ling CC, Endlich B: Radioresistance induced by oncogenic transformation. Radiat Res 120:267-279, 1989
50. Bernard EJ, Stanbridge EJ, Gupta S, et al: Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased radiation resistance in human tumor cell lines. Cancer Res 60:6597-6600, 2000
51. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage dependent and independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
52. Bernhard EJ, McKenna WG, Hamilton AD, et al: Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58:1754-1761, 1998
53. Cohen-Jonathan E, Muschel RJ, McKenna W, et al: Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125-132, 2000
54. Prevost GP, Pradines A, Brezak MC, et al: Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. Int J Cancer 91:718-722, 2001
55. Cohen-Jonathan E, Toulas C, Ader I, et al: The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res 152:404-411, 1999
56. Ader I, Toulas C, Dalenc F, et al: RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21:5998-6006, 2002
57. Verslype C, Van Steenbergen W, Humblet Y, et al: Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor R115777. Proc Am Soc Clin Oncol 20:171a, 2001 (abstr 681)
58. Zujewski J, Horak ID, Bol CJ, et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941, 2000
59. Hahn SM, Bernhard EJ, Regine W, et al: A phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002
60. Lewis TS, Shapiro PS, Abn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998
61. Klapper LN, Kirschbaum MH, Sela M, et al: Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79, 2000
62. Albanell J, Rojo F, Baselga J: Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839. Semin Oncol 28:56-66, 2001
63. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19:6594-6599, 2000
64. Price BD, Youmell MB: The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 56:246-250, 1996
65. Tian H, Wittmack EK, Jorgensen TJ: p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 60:679-684, 2000
66. Berger DH, Jardines LA, Chang H, et al: Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res 69:199-204, 1997
67. McPhillips F, Mullen P, Monia BP, et al: Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 85:1753-1758, 2001
68. Simon R, Richter J, Wagner U, et al: High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61:4514-4519, 2001
69. Riva C, Lavieille JP, Reyt E, et al: Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: Implication in drug and radioresistance. Eur J Cancer B Oral Oncol 316:384-391, 1995
70. Warenius HM, Jones M, German T, et al: Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer 83:1084-1095, 2000
71. Pirollo KF, Hao Z, Rait A, et al: Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 230:196-201, 1997
72. Gokhale PC, McRae D, Monia BP, et al: Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 9:191-201, 1999
73. Carter S, Auer KL, Reardon DB, et al: Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A43I human squamous carcinoma cells. Oncogene 16:2787-2796, 1998
74. Hagan M, Wang L, Hanley JR, et al: Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153:371-383, 2000
75. Liu Y, Martindale JL, Gorospe M, et al: Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 56:31-35, 1996
76. Jarvis WD, Fornari FA, Freemerman AJ, et al: Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol 52:935-947, 1997
77. Belka C, Knippers P, Rudner J, et al: MEK1 and Erk1/2 kinases as targets for the modulation of radiation responses. Anticancer Res 20:3243-3249, 2000
78. Grana TM, Rusyn EV, Zhou H, et al: Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62:4142-4145, 2002
79. Gupta AK, Bernard EJ, Bakanauskas VJ, et al: RAS-mediated radioresistance is not linked to the MAP kinase activation in two bladder carcinoma cell lines. Radiat Res 154:64-72, 2000
80. Dritschilo A, Huang C, Strauss L, et al: Liposome-encapsulated c-raf antisense oligodeoxynucleotide (LErafAON) in patients with advanced solid tumors: Phase I study of daily infusion during radiation therapy. Proc Am Soc Clin Oncol 21:28a, 2002 (abstr 107)
81. Dy G, Adjei AA: Novel targets for lung cancer therapy: Part I. J Clin Oncol 20:2881-2894, 2002
82. Gupta AK, McKenna WG, Weber CN, et al: Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885-892, 2002
83. Brognard J, Clark AS, Ni Y, et al: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997, 2001
84. Schultz RM, Merriman RL, Andis SL, et al: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 15:1135-1139, 1995
85. Hu L, Hofmann, Lu L, et al: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092, 2002
86. Schmidt-Ullrich RK, Dent P, Grant S, et al: Signal transduction and cellular radiation responses. Radiat Res 153:245-257, 2000
87. Jarvis WD, Grant S: Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17:227-240, 1999
88. Fournier DB, Chisamore M, Lurain JR, et al: Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: Possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol Oncol 81:366-372, 2001
89. Martinez-Gimeno C, Diaz-Meco MT, Dominguez I, et al: Alterations in levels of different protein kinase C isotopes and their influence on behavior of squamous cell carcinoma of the oral cavity: Epsilon PKC, a novel prognostic factor for relapse and survival. Head Neck 17:516-525, 1995
90. Carter L, Davis C, Lin PS, et al: Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism. Int J Radiat Biol 76:1323-1333, 2000
91. Sikpi MO, Wang Y: Ionizing radiation enhances double-strand-break repair in rapamycin-treated ataxia telangiectasia lymphoblasts. Int J Radiat Biol 76:177-187, 2000
92. Tenzer A ZA, Rocha D, Hemmings S, et al: The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC4I2, an inhibitor of protein kinase C. Cancer Res 61:8203-8210, 2001
93. Zaugg KRS, Resch H, Hegyi I, et al: Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC4I2. Cancer Res 61:732-738, 2001
94. Fabbro DR, Bodis S, Pruschy M, et al: PKC412: A protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17-28, 2000
95. Swannie HC, Kaye SB: Protein kinase C inhibitors. Curr Oncol Rep 4:37-46, 2002
96. Steel GG: The case against apoptosis. Acta Oncol 40:968-975, 2001
97. Brown JM, Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391-1399, 1999
98. Bromfield G, Bristow R: Relative importance of non-apoptotic and apoptotic cell death pathways in irradiated prostate cancer cells. Canadian Association of Radiation Oncology (CARO-ACRO) Annual Scientific Meeting, Quebec, Canada, September 21-23, 2001 (abstr A75)
99. Chang BD, Broude EV, Dokmanovic M, et al: A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59:3761-3767, 1999
100. Jiang K, Coppola D, Crespo NC, et al: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20:139-148, 2000
101. McKenna WG, Bernhard EJ, Markiewicz DA, et al: Regulation of radiation-induced apoptosis in oncogene-transfection of radiation-induced apoptosis in oncogene-transfected fibroblasts: Influence of H-ras on the G2 delay. Oncogene 12:237-245, 1996
102. Wen B, Deutsch E, Marangoni E, et al: Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85:2017-2021, 2001
103. Kimura K, Gelmann EP: Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem 275: 8610-8617, 2000
104. Li X, Stark GR: NFkappaB-dependent signaling pathways. Exp Hematol 30:285-296, 2002
105. Schmidberger H, Rave-Frank M, Lehmann J, et al: The combined effect of interferon beta and radiation on five human tumor cell lines and embryonal lung fibroblasts. Int J Radiat Oncol Biol Phys 43:405-412, 1999
106. Gruninger L, Cottin E, Li YX, et al: Sensitizing human cervical cancer cells in vitro to ionizing radiation with interferon beta or gamma. Radiat Res 152:493-498, 1999
107. Vokes EE: The promise of biochemical modulation in combined modality therapy. Semin Oncol 21:29-33, 1994
108. Jung M, Dritschilo A: NF-kappa B signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 11:346-351, 2001
109. Chien M, Astumian M, Liebowitz D, et al: In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 44:81-87, 1999
110. Kortmansky JS, Motwani MV, Jung CP, et al: Flavopiridol potentiates the effect of radiotherapy in HCT-116 colon cancer xenografts. Proc Am Soc Clin Oncol 21:87a, 2002 (abstr 347)
111. Tsuchida E, Urano M: The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. Int J Radiat Oncol Biol Phys 39:1153-1161, 1997
112. Xiao HH, Makeyev Y, Butler J, et al: 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. Radiat Res 158:84-93, 2002
113. Schmidberger H, Rave-Frank M, Lehmann J, et al: Radiosensitizing effect of natural and recombinant beta-interferons in a human lung carcinoma in vitro. J Cancer Res Clin Oncol 125:350-356, 1999
114. Wheldon TE, Mairs RJ, Rampling RP, et al: Modeling the enhancement of fractionated radiotherapy by gene transfer to sensitize tumour cells to radiation. Radiother Oncol 48:5-13, 1998
115. Mantovani G, Proto E, Massa E, et al: Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol 20:419-427, 2002
116. Buckner JC, Schomberg PJ, McGinnis WL, et al: A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92:420-433, 2001
117. Byhardt RW, Vaickus L, Win PL, et al: Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. J Interferon Cytokine Res 16:891-902, 1996
118. Hallahan DE, Spriggs DR, Beckett MA, et al: Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 86:10104-10107, 1989
119. Gridley DS, Hammond SN, Liwnicz BH: Tumor necrosis factor-alpha augments radiation effects against human colon tumor xenografts. Anticancer Res 14:1107-1112, 1994
120. Manetta A, Lucci J, Soopikian J, et al: In vitro cytotoxicity of human recombinant tumor necrosis factor alpha in association with radiotherapy in a human ovarian carcinoma cell line. Gynecol Oncol 38:200-202, 1990
121. Mauceri HJ, Hanna NN, Wayne JD, et al: Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 56:4311-4314, 1996
122. Nava VE, Cuvillier O, Edsall LC, et al: Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 60:4468-4474, 2000
123. Rocha S, Soengas MS, Lowe SW, et al: Protein kinase C inhibitor and irradiation-induced apoptosis: Relevance of the cytochrome c-mediated caspase-9 death pathway. Cell Growth Differ 11:491-499, 2000
124. Uchida H, Shinoura N, Kitayama J, et al: Caspase-8 gene transduction augments radiation-induced apoptosis in DLD-1 cells. Biochem Biophys Res Commun 292:347-354, 2002
125. Ruiter GA, Zerp SF, Bartelink H, et al: Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59:2457-2463, 1999
126. Chang BD, Watanabe K, Broude EV, et al: Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: Implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 97:4291-4296, 2000
127. Brugarolas J, Chandrarasekaran C, Gordon JI, et al: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995
128. Serrano M, Lin AW, McCurrach ME, et al: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and pi6INK4a. Cell 88:593-602, 1997
129. Crompton NE: Telomeres, senescence and cellular radiation response. Cell Mol Life Sci 53:568-575, 1997
130. Hoffmann W, Blase MA, Santo-Hoeltje L, et al: Radiation sensitivity of human squamous cell carcinoma cells in vitro is modulated by all-trans and 13-cis-retinoic acid in combination with interferon-alpha. Int J Radiat Oncol Biol Phys 45:991-998, 1999
131. DeBondt HL, Rosenblatt J, Jancarik J, et al: Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602, 1993
132. Sausville EA, Zaharevitz D, Gussio R, et al: Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target. Pharmacol Ther 82:285-292, 1999
133. Maity A, Kao GD, Muschel RJ, et al: Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys 37:639-653, 1997
134. Senderowicz AM: Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19:6600-6606, 2000
135. Paggi MG, Baldi A, Bonetto F, et al: Retinoblastoma protein family in cell cycle and cancer: A review. J Cell Biochem 62:418-430, 1996
136. Bernhard EJ, McKenna WG, Muschel RJ: Radiosensitivity and the cell cycle. Cancer J Sci Am 5:194-204, 1999
137. Deng C, Zhang P, Harper JW, et al: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684, 1995
138. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potent mediator of p53 tumor suppression. Cell 75:817-825, 1993
139. Wang Y, Li J, Booher RN, et al: Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 61:8211-8217, 2001
140. Bernhard EJ, Maity A, Muschel RJ, et al: Effects of ionizing radiation on cell cycle progression: A review. Radiat Environ Biophys 34:79-83, 1995
141. Senderowicz AM: Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19:6600-6606, 2000
142. National Cancer Institute: Clinical trials. http://www.cancer.gov/ clinicaltrials
143. Fan S, Chang JK, Smith ML, et al: Cells lacking CIPA/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127-2136, 1997
144. Li J, Wang Y, Sun Y, et al: Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res 157:322-330, 2002
145. McKenna WG, Iliakis G, Weiss MC, et al: Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Radiat Res 125:283-287, 1991
146. Milas L: Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11:290-299, 2001
147. Joki T, Heese O, Nikas DC, et al: Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60:4926-4931, 2000
148. Kirschenbaum A, Liu X, Yao S, et al: The role of cyclooxygenase-2 in prostate cancer. Urology 58:127-131, 2001
149. Koki AT, Harmon B, Woerner M, et al: Characterization of cyclooxygenase-2 (COX-2) expression and Her2/neu in human breast, colon, and prostate cancer. Proceedings of the 2000 AACR-NCI-EORTC International Conference. November 7-10, 2000, Amsterdam, the Netherlands (abstr 101)
150. Kang J, Kim E, Shin H, et al: The overexpression of cyclooxygenase-2 and antitumor effect of selective COX-2 inhibitor (SC-236) in gastric cancer. Proc Am Soc Clin Oncol 19:323a, 2000 (abstr 1279)
151. Williams CS, Sheng H, Brockman JA, et al: A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 3:428-436, 2001
152. Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93:497-506, 2001
153. Tsubouchi Y, Mukai S, Kawahito Y, et al: Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20:2867-2872, 2000
154. Liu XH, Kirschenbaum A, Yao S, et al: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164:820-825, 2000
155. Ding XZ, Tong WG, Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 20:2625-2631, 2000
156. Souza RF, Shewmake K, Beer DG, et al: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60:5767-5772, 2000
157. Furuta Y, Hall ER, Sanduja S, et al: Prostaglandins production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 48:3002-3007, 1988
158. Hanson WR, Jarnagin W, De Lauetiis K, et al: Modification of radiation injury of murine intestinal clonogenic cells and B-16 melanoma by PGI2 or flurbiprofen, in Walden TL (ed): Prostaglandin and Lipid Metabolism in Radiation Injury. New York, NY, Plenum Press, 1987, pp 331-338
159. Teicher BA, Bump EA, Palayoor S, et al: Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. Radiat Oncol Invest 4:221-230, 1996
160. Furuta Y, Hunter N, Barkley T, et al: Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 48:3008-3013, 1988
161. Pyo H, Choy H, Amorino GP, et al: A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7:2998-3005, 2001
162. Kishi K, Petersen S, Petersen C, et al: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326-1331, 2000
163. Dicker AP, Williams TL, Grant DS: Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24:438-442, 2001
164. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311, 2000
165. Sawaoka H, Tsuji S, Tsujii M, et al: Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79:1469-1477, 1999
166. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716, 1998
167. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
168. Teicher BA, Holden SA, Dupuis NP, et al: Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2:269-276, 1995
169. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
170. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
171. Geng L, Donnelly E, McMahon G, et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419, 2001
172. Ning S, Laird D, Cherrington JM, et al: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157:45-51, 2002
173. Kozin SV, Boucher Y, Hicklin DJ, et al: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39-44, 2001
174. Mauceri HJ, Hanna NN, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291, 1998
175. Gorski DH, Mauceri HJ, Salloum RM, et al: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58:5686-5689, 1998
176. Hanna NN, Seetharam S, Mauceri HJ, et al: Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 6:287-293, 2000
177. Dark GG, Hill SA, Prise VE, et al: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834, 1997
178. Lund EL, Bastholm L, Kristjansen PE: Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6:971-978, 2000
179. Landuyt W, Ahmed B, Nuyts S, et al: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49:443-450, 2001
180. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-902, 1998
181. Murata R, Siemann DW, Overgaard J, et al: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60:155-161, 2001
182. Salloum RM, Jaskowiak NT, Mauceri HJ, et al: NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res 60:6958-6963, 2000
183. Fox SB, Gasparini G, Harris AL: Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2:278-289, 2001
184. Kerbel RS: Clinical trials in antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J Clin Oncol 19:45S-51S, 2001 (suppl)
185. Yuan F, Chen Y, Dellian M, et al: Time dependent vascular regression and permeability changes in established human tumor xenograft induced by an anti-vascular endothelial growth factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996
186. Greenberger JS: Antitumor interaction of short course endostatin and ionizing radiation. Cancer J 6:279-281, 2000
187. Karkkainen MJ, Petrova TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19:5598-5605, 2000
188. Hess C, Vuong V, Hegyi I, et al: Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85:2010-2016, 2001
189. Saha D, Choy H, Cao Q, et al: Modulation of COX-2 expression and enhanced radio-sensitization in human lung carcinoma cells by tyrosine kinase inhibitor, SU-5416. Proc Am Soc Clin Oncol 21:445a, 2002 (abstr 1279)
190. Hoekman K, Kuenen B, Levi M, et al: Activation of the coagulation cascade and endothelial cell perturbation during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Proc Am Soc Clin Oncol 21:6a, 2002 (abstr 21)
191. Soff GA: Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 19:97-107, 2000
192. Griscelli F, Li H, Cheong C, et al: Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U S A 97:6698-6703, 2000
193. Eder JP Jr, Supko JG, Clark JW, et al: Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772-3784, 2002
194. Thomas JP, Arzoomanian RZ, Alberti D, et al: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223-231, 2003
195. Dicker AP, Anne P, Bonnani R, et al: Phase I trial results and preclinical studies of recombinant human angiostatin and external beam radiation therapy. Proc Am Soc Clin Oncol 21:7a, 2002 (abstr 23)
196. Kudelka AP, Levy T, Verschraegen CF, et al: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3:1501-1505, 1997
197. Murata R, Nishimura Y, Hiraoka M: An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37:1107-1113, 1997
198. Bonner JA, Maihle J, Folven BR, et al: The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29:243-247, 1994
199. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
200. Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995
201. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem: 14459-14464, 1997
202. Liu A, Du W, Liu JP, et al: RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20:6105-6113, 2000
203. Lebowitz PF, Prendergast GC: Non-ras targets of farnesyl transferase inhibitors: Focus on Rho. Oncogene. 17:1439-1445, 1998
204. Cox AD: Farnesyltransferase inhibitors: Potential role in the treatment of cancer. Drugs 61:723-732, 2001
205. Bichsel VE, Liotta LA, Petricoin EF: Cancer proteomics: From biomarker discovery to signal pathway profiling. Cancer J 7:69-78, 2001
206. Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism-The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 9:1047-1052, 1998
207. Korn EL, Arbuck S, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
208. Colevas AD, Brown JM, Haun T, et al: Development of investigational radiation modifiers. J Natl Cancer Inst 95:646-651, 2003
209. Von Hoff D: There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4:1079-1086, 1998